What?
EMOSIS promises a major change in diagnosing hemostasis disorders.
We have developed a series of simple-to-operate, high performance test kits. Each one uses a dedicated menu-driven benchtop flow cytometer to simply, quickly and accurately test for a broad range of hemostasis disorders.
Why?
CONFIRMING or disaffirming the suspicion of a hemostasis disturbance is essential in patient-focused best clinical practice.
Every year, millions of patients across all medical specialties are suspected of having a pathophysiological or drug-induced hemostasis disorders, which can prove disabling, or even fatal, if left untreated. Conversely, suspected cases that are later found to be normal may have been subjected to unnecessary treatment.
Who?
EMOSIS has assembled a high-performing team of specialists with a wealth of experience in myriad scientific, medical, industrial and business disciplines.
The range of skills brought by the members of this multinational, multidisciplinary team fully support our goal of fulfilling a pressing need felt by all practitioners involved in the care of patients with a suspected hemostasis disorder.
Video
Real-time in vivo thrombus formation (mouse model).
Injury immediately induces a series of events that, within 60 seconds, culminate in the development of a fibrin plug at the site of injury.
EMOSIS and Accellix announce intent to form a joint venture, EmoCellix
EmoCellix will focus on marketing a complete solution for hemostasis and thrombosis cytomolecular diagnostics
EMOSIS reinforces its Intellectual Property and scientific expertise
EMOSIS reinforces its Intellectual Property and scientific expertise
HIT Weekly Series Episode 6
The last episode of our weekly HIT Series, issued from Jean Amiral's white paper
Job offer : R&D Engineer
Emosis is seeking an R&D engineer . Download the job description and apply for this position !
HIT Weekly Series Episode 5
The fifth episode of our weekly HIT Series, issued from Jean Amiral's white paper
HIT Weekly Series Episode 4
The fourth episode of our weekly HIT Series, issued from Jean Amiral's white paper
HIT Weekly Series Episode 3
The third episode of our weekly HIT Series, issued from Jean Amiral's white paper
White paper- Introduction
Check out the first episode of our weekly posts about Heparin-Induced Thrombocytopenia (HIT), from the white paper written by Jean Amiral, CTO of Emosis.
Emosis raises another 1 million Euros from Cap Innov’Est
June 26th , 2018
Few days after initiating its commercial operations, Emosis raises another 1 million Euros from Cap Innov’Est, to fuel growth and innovation
Emosis announces an exclusive distribution agreement with 5-Diagnostics
Strasbourg and Basel, June 12th, 2018
Emosis announces an exclusive distribution agreement with 5-Diagnostics and the start of commercialization.
The company starts selling its first test, HIT Confirm®, through 5-Diagnostics’ international network.
EMOSIS announces CE Mark approval for HIT Confirm® kit
Strasbourg, France –March 20th, 2018
Emosis, a young medical device company specializing in cell-based hemostasis diagnostics, is thrilled to announce that the company recently CE-marked its first kit, the Emo-test HIT Confirm®. The company is about to start marketing its first in vitro diagnostic kit in cell-based Hemostasis